Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Esperion Therapeutics Inc maintains a gross margin of 52.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -11.41%, while the net margin is -35.89%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ESPR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ESPR competes directly with industry leaders such as ANNX and MPLT. With a market capitalization of $781.74M, it holds a significant position in the sector. When comparing efficiency, ESPR's gross margin of 52.71% stands against ANNX's N/A and MPLT's N/A. Such benchmarking helps identify whether Esperion Therapeutics Inc is trading at a premium or discount relative to its financial performance.
